LunaRx review

LunaRx currently lists tesamorelin, sermorelin, NAD⁺ and PT-141 in its peptide area, alongside GLP-1 injection, microdose and oral entries under weight loss. CJC-1295/ipamorelin and BPC-157 are absent from this catalog. The catalog displays NAD⁺ from $225/mo and sermorelin from $199/mo, while individual pages refer readers to consultation, so neither amount is a verified selected charge. Its GLP-1 homepage also shows conflicting $139/mo and $199/mo starting banners. State eligibility and the final stack price require review.

LunaRx LLC of Austin, Texas is a bilingual English/Spanish telehealth platform for GLP-1 programs and selected peptide therapies. Its current homepage describes Foundation as semaglutide with monthly check-ins and Premier as tirzepatide; neither current description establishes a CJC-1295/ipamorelin or NAD⁺ inclusion. Elite retains a two-month taper with GI-reset peptide support and B12. The public catalog lists semaglutide injection, GLP-1 microdose, oral GLP-1 and tirzepatide under weight loss, then tesamorelin, sermorelin, NAD⁺ and PT-141 in its peptide area. These listings do not verify that every formulation or stack is available for a particular patient.

A short online assessment leads to review by a licensed provider, who decides whether to prescribe; LunaRx says people who are not approved are not charged. The platform describes independent medical groups and licensed US partner pharmacies without naming the group or the dispenser. Its terms require adulthood and presence in a state where LunaRx operates, with the account and shipping state matching; it publishes no current state list. An initial order can be canceled within 24 hours only if it has not reached the provider network. Terms call for subscription cancellation at least 48 hours before processing, while a semaglutide page says 30 days notice; confirm the applicable deadline for your plan. Dispensed medication is generally nonrefundable.

The current catalog displays semaglutide injection from $139/mo, GLP-1 microdose and oral GLP-1 from $199/mo, tirzepatide injection from $149/mo, tesamorelin from $270/mo, sermorelin from $199/mo, NAD⁺ from $225/mo and PT-141 from $199/mo. Individual therapy pages describe sermorelin and NAD⁺ as available by consultation, so their catalog figures are starting displays, not confirmed selected debits. The homepage separately shows $139/mo and $199/mo GLP-1 starting banners; stack prices are confirmed after provider review. Terms describe an immediate bundled subscription debit and another every 30 days, including pharmacy, medical-group and platform fees. Dose, supply, any prepayment and the final debit are not public.

Compounded; not FDA-approved. Prescription follows only if a licensed provider finds it appropriate. LunaRx describes partner US compounding pharmacies but does not name a dispenser. Its current NAD⁺ page leaves route to the provider. The public catalog lists tesamorelin, sermorelin, NAD⁺ and PT-141; it does not currently list CJC-1295/ipamorelin or BPC-157. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the CJC-1295/ipamorelin blend is a growth-hormone secretagogue combination, CJC-1295 a GHRH analog that raises the baseline of growth hormone release and ipamorelin a selective ghrelin-receptor agonist that adds a pulse, so it works through your own pituitary rather than supplying growth hormone. The mechanism is real and well described. Human outcome data for the blend, and specifically for the lean-mass-preservation claim made for it during a GLP-1 caloric deficit, is thin; muscle loss on GLP-1 therapy is a genuine problem, but the evidence that a secretagogue blend fixes it is not there yet. BPC-157, TB-500, KPV and GHK-Cu have interesting laboratory and animal literature and essentially no controlled human outcome trials. Injected NAD⁺ has no controlled human outcome trials at all; the oral precursors NR and NMN are the forms with human data, and what they raise is a blood level. Individual results vary.